Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trialChristopher J. Sweeney, Kim Chi, Nicola Jane Lawrence et al.|The Lancet Oncology|2023Cited by 195
<scp>ABCC4</scp>/<scp>MRP4</scp> contributes to the aggressiveness of Myc‐associated epithelial ovarian cancerMoonSun Jung, Michelle J. Henderson, Jixuan Gao et al.|International Journal of Cancer|2020Cited by 15